Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
US Department of Justice
Chinese Patent Office

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,746,242

« Back to Dashboard

Which drugs does patent 8,746,242 protect, and when does it expire?

Patent 8,746,242 protects ARNUITY ELLIPTA, ANORO ELLIPTA, BREO ELLIPTA, and INCRUSE ELLIPTA , and is included in four NDAs.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 8,746,242

Title:Medicament dispenser
Abstract: A medicament dispenser for use with at least one medicament carrier carrying multiple distinct medicament portions, said medicament dispenser comprising (a) a dispensing mechanism actuable for dispensing the distinct medicament portions carried by the at least one medicament carrier; (b) a mouthpiece; and (c) a cover for the mouthpiece, the cover being movably mounted to the dispenser for sequential movement from a first position, in which the mouthpiece is covered, to a second position, in which the mouthpiece is at least part-uncovered, to a third position in which the mouthpiece is uncovered; wherein the cover is adapted to couple with the dispensing mechanism such that movement of the cover from the second position to the third position, but not the first position to the second position, results in actuation of the dispensing mechanism.
Inventor(s): Connell; Hugh Alexander (Evesham, GB), Harvey; Stephen James (Ware, GB), Tansley; Robert William (Bidford on Avon, GB)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:11/996,762
Patent Claim Types:
see list of patent claims
Composition; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
fluticasone furoate
POWDER;INHALATION205625-001Aug 20, 2014RXYesYes8,746,242► SubscribeY
fluticasone furoate
POWDER;INHALATION205625-002Aug 20, 2014RXYesYes8,746,242► SubscribeY
umeclidinium bromide; vilanterol trifenatate
POWDER;INHALATION203975-001Dec 18, 2013RXYesYes8,746,242► SubscribeY
Glaxo Grp Ltd
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-001May 10, 2013RXYesYes8,746,242► SubscribeY
Glaxo Grp Ltd
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 2015RXYesYes8,746,242► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,746,242

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0515584.1Jul 28, 2005
PCT Information
PCT FiledJuly 27, 2006PCT Application Number:PCT/GB2006/002831
PCT Publication Date:February 01, 2007PCT Publication Number: WO2007/012871

International Patent Family for Patent: 8,746,242

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico2008001250► Subscribe
South Korea101496791► Subscribe
South Korea20080031458► Subscribe
South Korea101425803► Subscribe
South Korea20130102134► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus